Eszopiclone for PTSD-Related Nightmares
Eszopiclone is not a recommended first-line agent for PTSD-associated nightmares and should generally be avoided in favor of evidence-based alternatives. The American Academy of Sleep Medicine 2018 guidelines do not include eszopiclone among recommended or even conditionally recommended treatments for PTSD-associated nightmares 1.
Why Eszopiclone Is Not Recommended
The 2018 AASM position paper explicitly states that image rehearsal therapy is the only recommended treatment for PTSD-associated nightmares 1. For pharmacotherapy, prazosin, clonidine, and several other agents "may be used," but eszopiclone is conspicuously absent from these recommendations 1. This omission is significant given the guideline's comprehensive review of available treatments.
While one small randomized controlled trial (n=24) showed eszopiclone 3 mg improved PTSD symptoms and sleep measures over 3 weeks 2, this single short-term study is insufficient to establish efficacy for PTSD-related nightmares specifically. The study was too brief to assess long-term safety or sustained benefit, and the sample size was inadequate for definitive conclusions.
If Eszopiclone Must Be Used Despite Limited Evidence
Starting Dose and Titration
- Start at 1 mg immediately before bedtime 3
- May increase to 2 mg or 3 mg if clinically indicated 3
- Maximum dose: 3 mg once daily 3
- Peak plasma concentrations occur 1.0-1.6 hours after dosing 4
Critical Contraindications and Precautions
Absolute contraindications:
- Severe hepatic impairment (maximum 2 mg if used) 3
- Concurrent use with potent CYP3A4 inhibitors (maximum 2 mg) 3
Pregnancy and breastfeeding:
- Avoid in pregnancy - no established safety data, and PTSD medications during pregnancy should prioritize SSRIs (sertraline, paroxetine) or venlafaxine when psychotherapy fails 5
- Avoid during breastfeeding - unknown if excreted in human milk 3
- PTSD in pregnancy is associated with increased risk of low birthweight (OR 2.05) and preterm birth (OR 1.23) 6, making untreated PTSD problematic, but eszopiclone is not an evidence-based choice
Elderly patients:
- Maximum dose: 2 mg 3
- Elimination half-life increases to approximately 9 hours in patients ≥65 years 4
- Higher risk of next-day impairment at 2-3 mg doses 3
Drug Interactions
- CNS depressants: Dose reduction required due to additive effects 3
- CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): Maximum 2 mg dose 3
- High-fat meals: Delays absorption and reduces sleep latency effects - take on empty stomach 3
Safety Monitoring
- Orthostatic hypotension risk - though less than with prazosin
- Common adverse effects: Unpleasant/bitter taste, headache, dry mouth, dizziness 4
- Withdrawal symptoms: Anxiety, abnormal dreams, nausea reported after discontinuation of 2-3 mg doses 4
- Abuse potential: Produces euphoria similar to diazepam 20 mg at supratherapeutic doses (6-12 mg) in individuals with benzodiazepine addiction history 4
- Next-day impairment: Monitor driving ability and alertness, particularly with 2-3 mg doses 3
Recommended Alternatives
For PTSD-associated nightmares, use evidence-based treatments instead:
- Image rehearsal therapy - the only Level A recommended treatment 1
- Prazosin - start 1 mg at bedtime, titrate by 1-2 mg every few days to effective dose (typically 3 mg, range 1-13 mg) 7
- Other pharmacologic options that "may be used": clonidine, trazodone, atypical antipsychotics (olanzapine, risperidone, aripiprazole), gabapentin, topiramate 1
Common Pitfall
Do not use eszopiclone simply because the patient has insomnia with PTSD. PTSD-associated nightmares require nightmare-specific treatment, not generic hypnotics. The pathophysiology involves elevated noradrenergic activity 7, which eszopiclone (a GABA-A receptor modulator) does not address.
The evidence strongly favors prazosin or image rehearsal therapy over eszopiclone for PTSD-related nightmares 1, 7.